Back to Search
Start Over
Predictors and Temporal Trends of Adjuvant Aromatase Inhibitor Use in Breast Cancer
- Source :
- Journal of the National Comprehensive Cancer Network. 7:115-121
- Publication Year :
- 2009
- Publisher :
- Harborside Press, LLC, 2009.
-
Abstract
- After the first report of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial, adjuvant aromatase inhibitor use increased rapidly among National Comprehensive Cancer Network member institutions. Increased aromatase inhibitor use was associated with older age, vascular disease, overexpression of human epidermal growth factor receptor 2 (HER2), or more advanced stage, and substantial variation was seen among institutions. This article examines adjuvant endocrine therapy in postmenopausal women after the first report of the trial, identifies temporal relationships in aromatase inhibitor use, and examines characteristics associated with choice of endocrine therapy among 4044 postmenopausal patients with hormone receptor-positive nonmetastatic breast cancer presenting from July 1997 to December 2004. Multivariable logistic regression analysis examined temporal associations and characteristics associated with aromatase inhibitor use. Time-trend analysis showed increased aromatase inhibitor and decreased tamoxifen use after release of ATAC results (P < .0001). In multivariable regression analysis, institution (P
- Subjects :
- Adult
Selective Estrogen Receptor Modulators
Oncology
medicine.medical_specialty
Neoplasms, Hormone-Dependent
Antineoplastic Agents, Hormonal
Receptor, ErbB-2
medicine.drug_class
medicine.medical_treatment
Breast Neoplasms
Breast cancer
Internal medicine
medicine
Adjuvant therapy
Humans
Practice Patterns, Physicians'
Aged
Randomized Controlled Trials as Topic
Aged, 80 and over
Aromatase inhibitor
Aromatase Inhibitors
business.industry
Vascular disease
Cancer
Middle Aged
medicine.disease
Gene Expression Regulation, Neoplastic
Postmenopause
Tamoxifen
Logistic Models
Endocrinology
Chemotherapy, Adjuvant
Female
business
Adjuvant
medicine.drug
Hormone
Subjects
Details
- ISSN :
- 15401413 and 15401405
- Volume :
- 7
- Database :
- OpenAIRE
- Journal :
- Journal of the National Comprehensive Cancer Network
- Accession number :
- edsair.doi.dedup.....603ebc5218668b0ab68de74db96c5a00